These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 7749028)

  • 1. [Calcitonin in the treatment of osteoporosis: its use in a basic health area].
    Cardona JM; Segui J; Siscar C
    Aten Primaria; 1995 Apr; 15(6):373-4, 376, 378-9. PubMed ID: 7749028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Variations in osteoporosis medication utilization. A population-based ecological cross-sectional study in the region of Valencia, Spain.
    Sanfélix-Gimeno G; Juliá-Sanchis ML; Librero J; Peiró S; García-Sempere A
    PLoS One; 2018; 13(6):e0199086. PubMed ID: 29927952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence and risk of venous thromboembolism among Taiwan osteoporotic fracture population under osteoporosis pharmacological treatments.
    Lin TC; Lee CH; Yang CY; Yang YH; Lin SJ
    J Clin Endocrinol Metab; 2014 May; 99(5):1599-607. PubMed ID: 24606074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The osteoporosis care gap in Canada.
    Papaioannou A; Giangregorio L; Kvern B; Boulos P; Ioannidis G; Adachi JD
    BMC Musculoskelet Disord; 2004 Apr; 5():11. PubMed ID: 15068488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Drugs prescription for osteoporosis].
    Erviti J
    An Sist Sanit Navar; 2003; 26 Suppl 3():107-21. PubMed ID: 14716363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences in adherence to osteoporosis regimens: a 2-year analysis of a population treated under specific guidelines.
    Cheng TT; Yu SF; Hsu CY; Chen SH; Su BY; Yang TS
    Clin Ther; 2013 Jul; 35(7):1005-15. PubMed ID: 23831360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calcitonin treatment of osteoporosis in Italy.
    Mazzuoli GF; Gennari C
    Lancet; 1992 Jul; 340(8811):120-1. PubMed ID: 1351993
    [No Abstract]   [Full Text] [Related]  

  • 8. [Calcitonin prescriptions: an estimate of the expenditure due to inadequate prescription].
    Kanterewicz E; Iruela A; Pladevall M; Serrarols M; Pañella D; Brugués J; Díez A
    Med Clin (Barc); 1998 Mar; 110(11):411-5. PubMed ID: 9608496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Calcitonin test].
    Zorzi R; Pescatori E
    Chir Ital; 1986 Jun; 38(3):321-5. PubMed ID: 3791535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The prescription of nonsteroidal anti-inflammatory and stomach-protector agents. Its adaptation to quality criteria in primary care].
    Sánchez Casado JI; Larrabe Medina J; Oscar Dosantos J; Ojer Tsakiridu D; Ruiz Tamayo R; Bilbao Izaguirre J; Sologuren Echenaguisía A
    Aten Primaria; 1997; 20(3):127-32. PubMed ID: 9303671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin.
    Sambrook P; Birmingham J; Kelly P; Kempler S; Nguyen T; Pocock N; Eisman J
    N Engl J Med; 1993 Jun; 328(24):1747-52. PubMed ID: 7684512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Drug consumption by people over 60 years of age in a rural area].
    Vega Quiroga S; López Gay L; Bermejo Pareja F; de la Rosa Gil L; de Bustos Tabernero M; Sampedro López MD; Fraile Jimeno M; Durán Parra F; Moreno Sobrino T; Gabriel Sánchez R
    Aten Primaria; 1996 May; 17(8):496-500. PubMed ID: 8679886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calcitonin nasal spray and increased cancer risk: a population-based nested case-control study.
    Sun LM; Lin MC; Muo CH; Liang JA; Kao CH
    J Clin Endocrinol Metab; 2014 Nov; 99(11):4259-64. PubMed ID: 25144633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The quality of antibacterial prescription in a primary care district. Its evolution in 1994-1995].
    García Lirola MA; Cabeza Barrera J; Ignacio García JM; Rabadán Asensio A
    Aten Primaria; 1997 May; 19(9):487-92. PubMed ID: 9264685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapeutic choices in osteoporosis].
    Burckhardt P
    Schweiz Med Wochenschr; 1987 Jan; 117(3):75-83. PubMed ID: 3823821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis.
    Hodsman AB; Fraher LJ; Ostbye T; Adachi JD; Steer BM
    J Clin Invest; 1993 Mar; 91(3):1138-48. PubMed ID: 8450043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Quality of life of patients suffering from osteoporosis treated with alendronate and salmon calcitonin].
    Sapuła RA; Ostrowski T; Bojar I
    Wiad Lek; 2002; 55 Suppl 1():444-7. PubMed ID: 15002282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The assessment of quality perceived by the users of the basic health areas of Cuenca].
    Retamal González A; Monge Jodrá V
    Aten Primaria; 1999 Nov; 24(9):507-13. PubMed ID: 10687218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Non-hormonal treatment of postmenopausal osteoporosis].
    Briançon D; Meunier PJ
    Rev Fr Gynecol Obstet; 1987 Dec; 82(12):713-8. PubMed ID: 3324271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health-related quality of life (HRQOL) in Japanese osteoporotic patients and its improvement by elcatonin treatment.
    Yoh K; Tanaka K; Ishikawa A; Ishibashi T; Uchino Y; Sato Y; Tobinaga M; Hasegawa N; Kamae S; Yoshizawa M
    J Bone Miner Metab; 2005; 23(2):167-73. PubMed ID: 15750696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.